Subscribe To

Price Alert Latest News Economic Calendar News

ENVB / Enveric Biosciences Closes $10 Million Public Offering

Psychedelics-based company Enveric Biosciences (NASDAQ:ENVB) has closed its previously announced underwritten public offering of 20 million shares of its common stock and warrants to purchase up to 20 million shares of its common stock for gross proceeds of approximately $10 million, before deducting underwriting discounts and commissions and other offering expenses. Transaction Details Enveric granted the underwriter a 45-day option to purchase up to an additional 3 million shares of common stock and/or warrants to purchase up to an additional 3 million shares of common stock at the public offering price, which the underwriter has partially exercised for warrants to purchase up to 3 million shares of common stock. Read More

Demo Live Account See Partner Details

Content Topics

Enveric

Biosciences

Closes

Million

Public

Offering

Stock

ENVB

Posted: Feb 16 2022, 07:49

Author Name: Benzinga

ENVB News

By InvestorPlace
May 18, 2023

Why Is Enveric Biosciences (ENVB) Stock Up 120% Today?

Enveric Biosciences (NASDAQ: ENVB ) stock is enlivened amid an otherwise soft early afternoon session on Wall Street, delivering triple-digit percenta

By Business Wire
February 22, 2023

Enveric Biosciences to Present at the Gravitas Securities Inc. 6th Annual Growth Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the d

By Business Wire
February 1, 2023

Enveric Biosciences to Present at the BIO CEO & Investor Conference

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the

By Business Wire
December 21, 2022

Enveric Biosciences to Present at the 6th Annual Neuroscience Innovation Forum and Biotech Showcase during "J.P. Morgan Health Care Week 2023"

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the

By Proactive Investors
March 15, 2022

Enveric Biosciences touts the publication of four patent applications for psychedelic-inspired drug candidates

Enveric Biosciences (NASDAQ:ENVB) Inc announced that the company's first four Patent Cooperation Treaty (PCT) applications for the tryptamine family o

By Proactive Investors
March 1, 2022

Enveric Biosciences files portfolio of patent applications for tryptamine derivatives

Enveric Biosciences (NASDAQ:ENVB) announced that it has filed its tenth Patent Cooperation Treaty (PCT) application directed to tryptamine-based deriv

By Proactive Investors
March 1, 2022

Enveric Biosciences files portfolio of patent applications for tryptamine derivatives

Enveric Biosciences (NASDAQ:ENVB) announced that it has filed its tenth Patent Cooperation Treaty (PCT) application directed to tryptamine-based deriv

By Proactive Investors
March 1, 2022

Enveric Biosciences files portfolio of patent applications for tryptamine derivatives

Enveric Biosciences (NASDAQ:ENVB) announced that it has filed its tenth Patent Cooperation Treaty (PCT) application directed to tryptamine-based deriv

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Subscribe To

Live Trading Account

Open live account in few minutes with just 10$

ENVB / Enveric Biosciences Closes $10 Million Public Offering

Enveric

Biosciences

Closes

Million

Public

Offering

Stock

ENVB

ENVB News

Why Is Enveric Biosciences (ENVB) Stock Up 120% Today?

Enveric Biosciences to Present at the Gravitas Securities Inc. 6th Annual Growth Conference

Enveric Biosciences to Present at the BIO CEO & Investor Conference

Enveric Biosciences to Present at the 6th Annual Neuroscience Innovation Forum and Biotech Showcase during "J.P. Morgan Health Care Week 2023"

Enveric Biosciences touts the publication of four patent applications for psychedelic-inspired drug candidates

Enveric Biosciences files portfolio of patent applications for tryptamine derivatives

Enveric Biosciences files portfolio of patent applications for tryptamine derivatives

Enveric Biosciences files portfolio of patent applications for tryptamine derivatives